Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences.
Randall J. Olsen,Randall J. Olsen,Paul A. Christensen,S. Wesley Long,S. Wesley Long,Sishir Subedi,Parsa Hodjat,Robert Olson,Robert Olson,Marcus Nguyen,Marcus Nguyen,James J. Davis,James J. Davis,Prasanti Yerramilli,Matthew Ojeda Saavedra,Layne Pruitt,Kristina Reppond,Madison N. Shyer,Jessica Cambric,Ryan Gadd,Rashi M. Thakur,Akanksha Batajoo,Ilya J. Finkelstein,Jimmy Gollihar,Jimmy Gollihar,James M. Musser,James M. Musser +26 more
Reads0
Chats0
TLDR
In this article, the trajectory of SARS-CoV2 variants circulating in a major metropolitan area, documents B.1.7 as the major cause of new cases in Houston, TX, and heralds the arrival of B.617 variants in the metroplex.Abstract:
Certain genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of substantial concern because they may be more transmissible or detrimentally alter the pandemic course and disease features in individual patients. SARS-CoV-2 genome sequences from 12,476 patients in the Houston Methodist health care system diagnosed from January 1 through May 31, 2021 are reported here. Prevalence of the B.1.1.7 (Alpha) variant increased rapidly and caused 63% to 90% of new cases in the latter half of May. Eleven B.1.1.7 genomes had an E484K replacement in spike protein, a change also identified in other SARS-CoV-2 lineages. Compared with non-B.1.1.7-infected patients, individuals with B.1.1.7 had a significantly lower cycle threshold (a proxy for higher virus load) and significantly higher hospitalization rate. Other variants [eg, B.1.429 and B.1.427 (Epsilon), P.1 (Gamma), P.2 (Zeta), and R.1] also increased rapidly, although the magnitude was less than that in B.1.1.7. Twenty-two patients infected with B.1.617.1 (Kappa) or B.1.617.2 (Delta) variants had a high rate of hospitalization. Breakthrough cases (n = 207) in fully vaccinated patients were caused by a heterogeneous array of virus genotypes, including many not currently designated variants of interest or concern. In the aggregate, this study delineates the trajectory of SARS-CoV-2 variants circulating in a major metropolitan area, documents B.1.1.7 as the major cause of new cases in Houston, TX, and heralds the arrival of B.1.617 variants in the metroplex.read more
Citations
More filters
Journal ArticleDOI
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas
Paul A. Christensen,Randall J. Olsen,S. Wesley Long,R. D. Snehal,James J. Davis,Matthew Ojeda Saavedra,K. Reppond,Madison N. Shyer,Jessica E. Cambric,Ryan D. H. Gadd,R. M. Thakur,A. Batajoo,R. Mangham,S Silva Peña,Tri Quang Trinh,Jacob C. Kinskey,Guy Williams,Robert Olson,Jimmy Gollihar,James M. Musser +19 more
TL;DR: In this article , a genome sequencing study of SARS-CoV-2 in the Houston Methodist health care system identified 4468 symptomatic patients with infections caused by Omicron (B.1.529) from late November 2021 through January 5, 2022.
Journal ArticleDOI
Multiple spillovers from humans and onward transmission of SARS-CoV-2 in white-tailed deer
Suresh V. Kuchipudi,Meera Surendran-Nair,Rachel Ruden,Michèle Gan Yon,Ruth H. Nissly,Kurt J. Vandegrift,Rahul K. Nelli,Lingling Li,Bhushan M. Jayarao,Costas D. Maranas,Nicole Levine,Katriina Willgert,Andrew J. K. Conlan,Randall J. Olsen,James J. Davis,James M. Musser,Peter J. Hudson,Vivek Kapur +17 more
TL;DR: The discovery of widespread infection of white-tailed deer indicates their establishment as potential reservoir hosts for SARS-CoV-2, a finding with important implications for the ecology, long-term persistence, and evolution of the virus, including the potential for spillback to humans.
Journal ArticleDOI
Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas.
Paul A. Christensen,Randall J. Olsen,S. Wesley Long,Sishir Subedi,James J. Davis,Parsa Hodjat,Debbie R. Walley,Jacob C. Kinskey,Matthew Ojeda Saavedra,Layne Pruitt,Kristina Reppond,Madison N. Shyer,Jessica Cambric,Ryan Gadd,Rashi M. Thakur,Akanksha Batajoo,Regan Mangham,Sindy Pena,Trina Trinh,Prasanti Yerramilli,Marcus Nguyen,Robert Olson,Richard Snehal,Jimmy Gollihar,James M. Musser +24 more
TL;DR: In this paper, the authors sequenced the genomes of 16,965 SARS-CoV-2 from samples acquired March 15, 2021 through September 20, 2021 in the Houston Methodist hospital system.
Journal ArticleDOI
Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas
TL;DR: The integrated analysis indicates that vaccines used in the United States are highly effective in decreasing severe acute respiratory syndrome coronavirus disease 2019 (COVID-19) pandemic, hospitalizations, and deaths as mentioned in this paper .
Journal ArticleDOI
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
TL;DR: In 2019, the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) separately developed a categorization system for differentiating new strains of SARS-CoV-2 into variants of concern and variants of interest as mentioned in this paper .
References
More filters
Journal ArticleDOI
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Katherine R. W. Emary,Tanya Golubchik,Parvinder K. Aley,Cristina V. Ariani,Brian Angus,S Bibi,Beth Blane,David Bonsall,P Cicconi,Sue Charlton,Elizabeth A. Clutterbuck,Andrea M. Collins,Tony Cox,Thomas C. Darton,Christina Dold,Alexander D. Douglas,Christopher J A Duncan,Christopher J A Duncan,Katie J. Ewer,Amy Flaxman,Saul N. Faust,Saul N. Faust,Daniela M. Ferreira,Shuo Feng,Adam Finn,P M Folegatti,Michelle Fuskova,Eva P. Galiza,Anna L. Goodman,Anna L. Goodman,Catherine M. Green,Christopher A Green,Melanie Greenland,Bassam Hallis,Paul T. Heath,Jodie Hay,Helen Hill,D Jenkin,Simon Kerridge,Rajeka Lazarus,Vincenzo Libri,Patrick J. Lillie,Catherine Ludden,N G Marchevsky,Angela M. Minassian,Alastair McGregor,Yama F Mujadidi,Daniel J. Phillips,Emma Plested,Katrina M Pollock,Hannah Robinson,Andrew Smith,R Song,Matthew D. Snape,Rebecca K. Sutherland,E. Thomson,E. Thomson,Mark Toshner,David P. J. Turner,David P. J. Turner,Johan Vekemans,Tonya Villafana,Christopher Williams,Christopher Williams,Adrian V. S. Hill,Teresa Lambe,Sarah C. Gilbert,Merryn Voysey,M N Ramasamy,Andrew J. Pollard +69 more
TL;DR: A post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against B.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020 as discussed by the authors.
Journal ArticleDOI
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
Alexander Muik,Ann-Kathrin Wallisch,Bianca Sänger,Kena A. Swanson,Julia Mühl,Wei Chen,Hui Cai,Daniel Maurus,Ritu Sarkar,Özlem Türeci,Philip R. Dormitzer,Ugur Sahin +11 more
TL;DR: In this paper, the authors tested SARS-CoV-2-S pseudovirus bearing either the Wuhan reference strain or the B.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA-based COVID-19 vaccine BNT162b2.
Journal ArticleDOI
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
P Supasa,D. Zhou,Wanwisa Dejnirattisai,Chang Liu,Alexander J. Mentzer,Helen M. Ginn,Yuguang Zhao,Duyvesteyn Hme.,R Nutalai,Aekkachai Tuekprakhon,Beibei Wang,Guido C. Paesen,J Slon-Campos,Cesar Lopez-Camacho,Bassam Hallis,Naomi Coombes,Kevin R. Bewley,Sue Charlton,Thomas S. Walter,Eleanor Barnes,Susanna Dunachie,Donal T. Skelly,Sheila F Lumley,Natalie Baker,I Shaik,Holly E. Humphries,Kerry J Godwin,N Gent,A Sienkiewicz,Christina Dold,R Levin,Tao Dong,Andrew J. Pollard,Julian C. Knight,Paul Klenerman,D W Crook,Teresa Lambe,Elizabeth A. Clutterbuck,S Bibi,Amy Flaxman,M Bittaye,Sandra Belij-Rammerstorfer,Sarah C. Gilbert,David R. Hall,Mark A. Williams,Neil G. Paterson,William James,Miles W. Carroll,Elizabeth E. Fry,Juthathip Mongkolsapaya,Jingshan Ren,David I. Stuart,Gavin R. Screaton +52 more
TL;DR: In this article, the authors examined the ability of B.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination, and found that B. 1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light chain contacts with residue 501.
Posted ContentDOI
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
Kai Wu,Anne P. Werner,Juan I. Moliva,Matthew A. Koch,Angela Choi,Guillaume Stewart-Jones,Hamilton Bennett,Seyhan Boyoglu-Barnum,Wei Shi,Barney S. Graham,Andrea Carfi,Kizzmekia S. Corbett,Robert A. Seder,Darin K. Edwards +13 more
TL;DR: In this paper, the authors assessed the neutralizing capacity of sera from human subjects or non-human primates (NHPs) that received mRNA-1273 vaccination, using two orthogonal VSV and lentivirus PsVN assays expressing spike variants of 20E (EU1), 20A.7, and B.1.351.
Journal ArticleDOI
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
Xianding Deng,Miguel Garcia-Knight,Mir M. Khalid,Venice Servellita,Candace Wang,Mary Kate Morris,Alicia Sotomayor-Gonzalez,Dustin R. Glasner,Kevin Reyes,Amelia S. Gliwa,Nikitha P. Reddy,Claudia Sanchez San Martin,Scot Federman,Jing Cheng,Joanna Balcerek,Jordan E. Taylor,Jessica Streithorst,Steve Miller,Bharath Sreekumar,Pei-Yi Chen,Ursula Schulze-Gahmen,Taha Y. Taha,Jennifer M. Hayashi,Camille R. Simoneau,G. Renuka Kumar,Sarah McMahon,Peter V. Lidsky,Yinghong Xiao,Peera Hemarajata,Nicole M. Green,Alex Espinosa,Chantha Kath,Monica Haw,John Bell,Jill K. Hacker,Carl L. Hanson,Debra A. Wadford,Carlos Anaya,Donna Ferguson,Phillip A. Frankino,Haridha Shivram,Liana F. Lareau,Stacia K. Wyman,Melanie Ott,Melanie Ott,Raul Andino,Charles Y. Chiu +46 more
TL;DR: In this article, the authors identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the western United States.
Related Papers (5)
Association of E484K spike protein mutation with SARS-CoV-2 infection in vaccinated persons---Maryland, January - May 2021.
Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021.
Kenneth A. Feder,Marcia Pearlowitz,Alexandra Goode,Monique Duwell,Thelonious W. Williams,Ping An Chen-Carrington,Ami Patel,Catherine Dominguez,Eric N. Keller,Liore Klein,Alessandra Rivera-Colon,Heba H. Mostafa,C. Paul Morris,Neil Patel,Anna M. Schauer,Robert Myers,David Blythe,Katherine A. Feldman +17 more